CA2857019C - Soluble tandem selectin glycoprotein ligand molecules - Google Patents

Soluble tandem selectin glycoprotein ligand molecules Download PDF

Info

Publication number
CA2857019C
CA2857019C CA2857019A CA2857019A CA2857019C CA 2857019 C CA2857019 C CA 2857019C CA 2857019 A CA2857019 A CA 2857019A CA 2857019 A CA2857019 A CA 2857019A CA 2857019 C CA2857019 C CA 2857019C
Authority
CA
Canada
Prior art keywords
tsgl
molecule
polypeptide
psgl
glycoprotein ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2857019A
Other languages
English (en)
French (fr)
Other versions
CA2857019A1 (en
Inventor
Gray D. Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2857019A1 publication Critical patent/CA2857019A1/en
Application granted granted Critical
Publication of CA2857019C publication Critical patent/CA2857019C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2857019A 2011-11-28 2012-11-28 Soluble tandem selectin glycoprotein ligand molecules Active CA2857019C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564275P 2011-11-28 2011-11-28
US61/564,275 2011-11-28
PCT/US2012/066910 WO2013082200A1 (en) 2011-11-28 2012-11-28 Novel enhanced selectin antagonists

Publications (2)

Publication Number Publication Date
CA2857019A1 CA2857019A1 (en) 2013-06-06
CA2857019C true CA2857019C (en) 2022-08-16

Family

ID=48467086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2857019A Active CA2857019C (en) 2011-11-28 2012-11-28 Soluble tandem selectin glycoprotein ligand molecules

Country Status (5)

Country Link
US (1) US8889628B2 (enExample)
EP (1) EP2785843B1 (enExample)
JP (1) JP6181066B2 (enExample)
CA (1) CA2857019C (enExample)
WO (1) WO2013082200A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914470C (en) 2013-06-03 2022-09-27 Emory University Selectin inhibitors, composition, and uses related thereto
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
US12479904B2 (en) 2017-12-29 2025-11-25 Gray D Shaw Methods of treating cytokine release syndrome by administering a molecule comprising a soluble tandem selectin glycoprotein ligand
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
US20230303657A1 (en) * 2020-03-10 2023-09-28 Gray D Shaw Fusion Molecules of PSGL-1 or TSGL Anionic Domains to Checkpoint-Modulating Antibodies and Other Antibodies
WO2023049265A1 (en) * 2021-09-23 2023-03-30 Beth Israel Deaconess Medical Center, Inc. P-selectin inhibitors and uses thereof
WO2026080432A1 (en) * 2024-10-07 2026-04-16 Beth Israel Deaconess Medical Center, Inc. Dimeric p-selectin inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
WO2000065068A1 (en) * 1999-04-23 2000-11-02 Ceptyr, Inc. Dsp-10 dual-specificity map kinsase phosphatase
NZ521687A (en) * 2000-03-31 2004-11-26 Inst Genetics Llc Modulating, e.g., preventing, inhibiting or treating thrombosis, comprising administering a P-selectin antagonist to subject with cardiovascular disorder such as atherosclerosis or hypertension
US20040086519A1 (en) * 2000-09-12 2004-05-06 Genetics Institute, Llc Inhibition of stenosis or restenosis by P-selectin ligand antagonists
CA2457400A1 (en) * 2001-08-03 2003-02-20 Genetics Institute, Llc Modulation of leukocyte-endothelial interactions following ischemia
CA2622772A1 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme

Also Published As

Publication number Publication date
WO2013082200A1 (en) 2013-06-06
JP6181066B2 (ja) 2017-08-16
JP2014534266A (ja) 2014-12-18
EP2785843A4 (en) 2015-07-29
EP2785843B1 (en) 2019-03-06
US20130136741A1 (en) 2013-05-30
CA2857019A1 (en) 2013-06-06
US8889628B2 (en) 2014-11-18
EP2785843A1 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
US8889628B2 (en) Soluble tandem selectin glycoprotein ligand molecules
US12195518B2 (en) Methods for treating cancer using soluble forms of PSGL-1 and fusion molecules thereof
AU660627B2 (en) Functionally active selectin-derived peptide for GMP-140
US6506382B2 (en) Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand
US6458360B1 (en) Soluble complement regulatory molecules
US5198424A (en) Functionally active selectin-derived peptides
CA2151142C (en) Glycoprotein ligand for p-selectin and methods of use thereof
EP0602194A1 (en) Peptide inhibitors of inflammation mediated by selectins
EP0639224B1 (en) Lectin domain variants of selectin
US20230303657A1 (en) Fusion Molecules of PSGL-1 or TSGL Anionic Domains to Checkpoint-Modulating Antibodies and Other Antibodies
JPH05501398A (ja) 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ）
US9266923B2 (en) Compositions and methods for treatment of thrombosis and for prolonging survival of stored platelets
Prodinger Complement receptor type two (CR2, CR21) A target for influencing the humoral immune response and antigen-trapping
US20150203576A1 (en) Variants of IgG Fc with Limited Amine Groups
US10214578B1 (en) Variants of IgG-Fc fusion that provide for site-specific conjugation at the N-terminus
WO2013096932A1 (en) Compositions and methods for treatment of thrombosis and prolonging survival of stored platelets
JP2000143694A (ja) 血小板由来白血球貪食能亢進因子の活性化因子
CA2512399A1 (en) F11 receptor(f11r) antagonists as therapeutic agents
EP1245575A2 (en) Functionally active selectin-derived peptides and ligand for GMP140

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - SMALL

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260109

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260713